• by Bruce Carlson
  • November 30 2018
  • HIV
  • IVD


The Latest Developments in HIV Diagnostic Testing

The Latest Developments in HIV Diagnostic Testing

HIV remains a deadly disease, but fortunately, in vitro diagnostic solutions abound for its detection and treatment progress-tracking. From utilizing dentists, to making tests available on more analyzer systems, we track the developments in HIV IVD in this articlee. More information can be found in our Worldwide Market for In Vitro Diagnostics Tests, 11th Edition

  • by Bruce Carlson
  • November 12 2018
  • IVD


7 Things We're Excited About at MEDICA 2018

7 Things We're Excited About at MEDICA 2018

As the well-attended and prestigious medical tradeshow begins in Dusseldorf, here's seven things we are finding interest in. Many in our core areas of in vitro/in vivo diagnostics, but there are some interesting device therapies that can't be ignored. Watch for more developments as the meeting continues.


CVS-Aetna Merger and Walgreens-LabCorp Partnership: Assessing The Impact

CVS-Aetna Merger and Walgreens-LabCorp Partnership: Assessing The Impact

The two largest pharmacy chains both made very big competitive moves in the same month. CVS merged with healthcare insurance provider Aetna. Walgreens partnered with LabCorp. Both events are a good sign for the market for in vitro diagnostics, as we explain in this article.


Next Generation Sequencing Continues to Make Strides: Neonatal Screening, Onco-genomics, Infectious Disease Dx, and More

Next Generation Sequencing Continues to Make Strides: Neonatal Screening, Onco-genomics, Infectious Disease Dx, and More

A quick look into some of the latest developments in the next generation sequencing segment, announced since the publication of the latest edition of our IVD report.

  • by Bruce Carlson
  • September 11 2018
  • IVD


5 Fast Facts About the IVD Market

The world market for diagnostics is estimated at $65 billion in 2018 and is expected to grow 4% annually to $77.8 billion by 2023. This includes all laboratory and hospital-based products, and OTC product sales. Previous editions had growth at 5-6%. growth has lowered due to reimbursement limitations. Yet there is plenty of reason for optimism too.

  • by Bruce Carlson
  • July 27 2018
  • IVD


20+ Things We're Excited About Seeing at AACC 2018

20+ Things We're Excited About Seeing at AACC 2018

A preview of announced developments at the upcoming American Association for Clinical Chemistry meeting in Chicago, which starts July 29th.


Lab Test Harmonization Gets a $2 Million Boost

Lab Test Harmonization Gets a $2 Million Boost

Recently the AACC released a statement applauding $2 million in funding given to the CDC to advance the cause of harmonizing and standardizing clinical lab test results. The pathology community has been pursuing this for decades, in the name of improving diagnoses and treatment as well as to reduce health care costs.


The CRISPR Diagnostic Toolkit Gets Handier

The CRISPR Diagnostic Toolkit Gets Handier

A new platform based on the gene editing technique is unveiled, and an old-but-still-pretty-new method gets an update. Plus, a CRISPR-related retraction.

  • by Bruce Carlson
  • February 6 2018
  • IVD


5 IVD Market Trends to Watch in 2018

5 IVD Market Trends to Watch in 2018

From syndromic testing to the microbiome, watch these five in vitro diagnostic market trends as they develop this year.


IVD Can Contribute to t-mAb Effectiveness

Therapeutic monoclonal antibodies are useful therapies but in some cases they work for a period, then lose their effectiveness The role of testing in preventing therapeutic monoclonal antibodies from failing has recently received high-profile attention, with a session at AACC and in other places This blog piece by Kalorama analyst Rob Camp, PhD, looks at the role of testing.